Skip to main content

Changing the landscape in
Life-Threatening Diseases

At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.

Our Pipeline

Reata’s development programs have created a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.

Pipeline
Discovery
Preclinical
Phase 1
Phase 2
Pivotal
NDA*
Chronic Kidney Disease
Alport Syndrome | Bardoxolone* Alport Syndrome
Bardoxolone
Autosomal Dominant Polycystic Kidney Disease | Bardoxolone ADPKD
Bardoxolone
IgA Nephropathy | Bardoxolone IgA Nephropathy
Bardoxolone
Type 1 Diabetes | Bardoxolone Type 1 Diabetes
Bardoxolone
Focal Segmental Glomerulosclerosis | Bardoxolone FSGS
Bardoxolone
At Risk of Rapid Progression | Bardoxolone Rapid Progression
Bardoxolone
Neurology
Friedreich's Ataxia | Omaveloxolone** Friedrecih's Ataxia
Omaveloxolone
Diabetic Peripheral Neuropathic Pain | RTA 901 DPNP
RTA 901
Other
Autoimmune Indications | RTA 1701 Autoimmune
RTA 1701

Bardoxolone = Bardoxolone methyl; *NDA accepted for filing by the FDA; **Subject to discussion with regulatory authorities

Bardoxolone methyl, omaveloxolone, RTA 901, and RTA 1701 are investigational drugs. Safety and efficacy have not been established by any agency.

image oval image oval2

Latest News

More News

Careers

We are a team of problem solvers, trailblazers, and people who want to make a difference.

Learn More
Dawn of a New Era